Compare EVER & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVER | OCGN |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.6M | 492.5M |
| IPO Year | 2018 | 2014 |
| Metric | EVER | OCGN |
|---|---|---|
| Price | $17.67 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $27.00 | $9.75 |
| AVG Volume (30 Days) | 770.5K | ★ 6.4M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 198.86 | 31.58 |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $163,349,000.00 | N/A |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $11.51 | $1,718.38 |
| P/E Ratio | $35.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.88 | $0.90 |
| 52 Week High | $28.73 | $2.73 |
| Indicator | EVER | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 35.15 |
| Support Level | $17.25 | $1.30 |
| Resistance Level | $26.33 | $1.92 |
| Average True Range (ATR) | 1.06 | 0.06 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 11.99 | 17.50 |
EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").